$PAND +133% today an acquisition news

$PAND who is a clinical stage biopharmaceutical company developing novel therapeutics designed to address the unmet needs of patients suffering from autoimmune diseases just today after Merck & Co ($MRK) offer $60 per share in cash.

Here is the link of the press release.

Here is the graph of the day.

Here is the 30-day overview.